The contact-mediated response of peripheral-blood monocytes to preactivated T cells is suppressed by serum factors in rheumatoid arthritis by Rossol, Manuela et al.
Open Access
Available online http://arthritis-research.com/content/7/6/R1189
R1189
Vol 7 No 6 Research article
The contact-mediated response of peripheral-blood monocytes to 
preactivated T cells is suppressed by serum factors in rheumatoid 
arthritis
Manuela Rossol1, Sylke Kaltenhäuser1, Roger Scholz2, Holm Häntzschel1, Sunna Hauschildt3 and 
Ulf Wagner1
1Department of Medicine IV, University of Leipzig, Leipzig, Germany
2Department of Orthopedics, University of Leipzig, Leipzig, Germany
3Department of Immunobiology, Institute of Zoology, University of Leipzig, Leipzig, Germany
Corresponding author: Ulf Wagner, wagu@medizin.uni-leipzig.de
Received: 3 Mar 2005 Revisions requested: 17 Mar 2005 Revisions received: 16 Jul 2005 Accepted: 20 Jul 2005 Published: 17 Aug 2005
Arthritis Research & Therapy 2005, 7:R1189-R1199 (DOI 10.1186/ar1804)
This article is online at: http://arthritis-research.com/content/7/6/R1189
© 2005 Rossol et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Stimulation of monocytes/macrophages after cell contact with
preactivated T cells has been suggested to contribute to the
excessive TNF-α production in rheumatoid arthritis (RA). In this
study, T cell-contact-dependent TNF-α production by
peripheral-blood monocytes in vitro was investigated and found
to be significantly lower in treated and untreated patients with
RA than in healthy controls. This suppression was not due to a
general deficiency of monocytes to respond, because
responses to lipopolysaccharide were comparable in patients
and controls. In agreement with the pivotal role of TNF-α in RA,
T cell-dependent induction of TNF-α in synovial macrophages
was fivefold to tenfold higher than in peripheral-blood
monocytes from either patients or controls. The decreased
response of peripheral-blood monocytes from patients with RA
was found to be mediated by inhibitory serum factors, because
the addition of patient sera to monocytes from healthy controls
suppressed TNF-α response in the co-culture assay.
Preincubation of monocytes from healthy controls with RA
serum was sufficient to suppress the subsequent TNF-α
response in T cell co-cultures, indicating that inhibitory factors
do indeed bind to monocyte surfaces, which might represent a
regulatory counter-action of the immune system to the long-
standing and consuming autoimmune process in RA. There are
some indications that apolipoprotein A-1 might be part of this
regulatory system.
Introduction
Cytokine production by monocytes/macrophages at sites of
active inflammation is an important mechanism in the initiation
and perpetuation of various chronic autoimmune diseases
including type I diabetes mellitus, multiple sclerosis and rheu-
matoid arthritis (RA). The signals triggering this proinflamma-
tory cytokine secretion in vivo are not completely understood.
Although bacterial endotoxins such as lipopolysaccharide
(LPS) and other microbial products are major stimuli of mono-
cyte activation in infectious diseases, they are not considered
to be relevant stimuli in autoimmune settings. So far, the most
powerful known pathway inducing monocyte cytokine secre-
tion in vivo in non-infectious situations is the direct cellular
interaction with preactivated T cells [1].
The cell surface molecules involved in this T cell-dependent
monocyte activation have been extensively investigated. T cell
surface molecules, some of them upregulated on activation,
such as CD69 [2,3], CD23 [4,5], integrins [6], CD40-CD40
ligand [7], LAG-3 [8], CD45 [9], LFA-1 and ICAM-1 [10] and
membrane-bound cytokines [11] have all been implicated in
this activation.
In RA, elevated levels of monocytic cytokines such as tumour
necrosis factor (TNF)-α and IL-1β are present in the synovial
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membrane of diseased joints. Their relevance to disease
pathogenesis has been highlighted by the clinical success of
therapeutic strategies neutralizing TNF-α or IL-1β [12-14].
CD4+ T cells, in contrast, have initially been implied in the
pathogenesis of the disease because of the association of
related HLA DRB1 alleles with susceptibility to and severity of
the disease, and have subsequently been found to exhibit
numerous pathological features such as oligoclonal expan-
sions, contraction of T cell receptor repertoire, shortened tel-
omere fragments indicative of increased replicative history,
and distinct pathological phenotypes [15-19]. The traditionally
described paucity of cytokines of T cell origin in the RA syno-
vial membrane, which has been considered an argument
against the involvement of T cells in the pathogenesis of the
disease, has been put into perspective by the more recent rec-
ognition of high levels of IL-15 [20], IL-17 and, although at low
levels, IFN-γ [21] in rheumatoid joints.
The monocytic production of TNF-α and IL-1 in RA synovial
membranes seems to be independent of T cell cytokines. It
has therefore been suggested that the direct interaction of
activated T cells with monocytes, rather than the T cell-based
production of cytokines, is a major stimulus of the excessive
levels of TNF-α and IL-1β in RA. In addition, monocytes have
been shown to be able to produce matrix metalloproteinases
after contact with T helper type 2 (Th2) cells [22], which fur-
ther implicates this interaction in the breakdown of extracellu-
lar matrix and subsequent joint destruction in RA.
To investigate cell-contact-mediated activation of monocytes
by preactivated T cells, monocytic cell lines or monocytes from
healthy donors have been primarily used in co-culture with T
cells from healthy donors [8,11,23-26]. Disease-relevant
CD4+ T cells isolated from the synovial membrane of patients
with RA were also used as stimulators and found to be potent
inducers of cytokine production in monocytic THP-1 cells [27],
in monocytes from healthy donors [10,28] and in mononuclear
cells isolated from synovial membranes of patients with RA
[29]. So far, peripheral-blood monocytes of patients with RA
have not been analysed for T cell-dependent cytokine secre-
tion, although the involvement of circulating monocytes in the
disease process has been suggested [30-32]. Here we show
that the T cell-dependent response of monocytes is sup-
pressed in RA and that serum factors contribute to this inhibi-
tion, most probably by coating monocyte cell surfaces.
Materials and methods
Patients and controls
Twenty patients with RA as defined by the 1987 revised crite-
ria of the American College of Rheumatology [33] were
enrolled into the initial study. The study design was approved
by the University of Leipzig's Ethics Committee, and informed
consent was obtained from each patient before study enrol-
ment. Sixteen of the patients had rheumatoid factor (RF) IgM
seropositive disease, and 15 patients expressed the RA-asso-
ciated shared epitope (on either a DRB1*01 or a DRB1*04
allele).
The median age of the patients was 59 years (range 22 to 74).
For each patient, an age-matched control was selected from
healthy volunteers. Clinical parameters documented at the
time of presentation to the outpatient department included
tender and swollen joint count, and concentrations of C-reac-
tive protein (CRP) and of RF IgM.
Six patients had recent-onset RA (disease duration less than
2 years) and had not received therapy with disease-modifying
anti-rheumatic drugs (DMARD) before inclusion in the study.
The median disease duration for the 14 patients receiving
DMARD was 9.5 years (interquartile range 5.0 to 11.0). Cur-
rent treatment regimens included methotrexate alone (n = 5)
or in combination with cyclosporine A (n = 1) or hydroxychlo-
quine (n = 1), intramuscular gold injections (n = 1), lefluno-
mide (n = 1) or TNF-α-blocking agents (n = 5).
For analysis of the T cell-dependent response of synovial mac-
rophages, synovial biopsy specimens were obtained from six
patients with RA and active synovitis who underwent synovec-
tomy in the Department of Orthopedics at Leipzig University.
Synovectomized joints were elbow joints (n = 2), metacar-
pophalangeal joints (n = 1), ankle joints (n = 2), knee joint (n
= 1) and wrist (n = 1). Five of the patients had RF IgM-positive
disease; the median CRP was 14.6 mg/l. Three of the patients
received no immunosuppressive therapy, whereas two
patients were treated with methotrexate and one was treated
with etanercept.
To explore the influence of clinical parameters of the disease
on inhibitory serum activity, two additional patient cohorts
were recruited. Twenty patients with non-active disease (CRP
below 10 mg/l and not more than swollen joints) were identi-
fied from a pre-existing institutional serum bank and compared
with 20 patients with intermediate to high disease activity
(mean CRP 35.6, median swollen joint count 14, median ten-
der joint count 18). As control groups with systemic inflamma-
tory disease, sera from 9 patients with ankylosing spondylitis
and from 9 patients with psoriatic arthritis were used.
Isolation of monocytes
Peripheral-blood mononuclear cells (PBMCs) were obtained
by Ficoll®-Paque (Pharmacia Biotech, Freiburg, Germany)
density-gradient centrifugation [34]. After repeated washing in
PBS containing EDTA, monocytes were isolated by negative
magnetic depletion with hapten-conjugated CD3, CD7,
CD19, CD45RA, CD56 and anti-IgE antibodies (MACS;
Miltenyi Biotech, Bergisch Gladbach, Germany) and a mag-
netic cell separator (MACS) in accordance with the manufac-
turer's protocol. The cell preparations were more than 95%
monocytes as determined by morphology andAvailable online http://arthritis-research.com/content/7/6/R1189
R1191
immunofluorescence staining with a monoclonal antibody
against CD14 (BL-M/G14).
To obtain larger amounts of monocytes, PBMCs were sepa-
rated by counterflow centrifugation with the J6-MC elutriator
system (Beckmann Instruments, Palo Alto, CA, USA) as
described previously [35]. The cell preparations were more
than 90% monocytes as determined by morphology and
immunofluorescence staining with a monoclonal antibody
against CD14 (BL-M/G14). In the co-culture assays
described below, the response of monocytes separated by
this technique was indistinguishable from that of monocytes
obtained by immunomagnetic separation (data not shown).
Separation of human synovial macrophages from 
patients with RA
Synovial tissue specimens were cut into 2 to 4 mm3 pieces
and washed once in complete medium (RPMI 1640, 10%
FCS, 200 µM L-glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin). Then, 1 cm3 of tissue was incubated in 10 ml of
digestion solution (0.05 M HEPES buffer, 3 mg/ml type 1A
collagenase, 1 mg/ml hyaluronidase, 0.1 mg/ml type IV deox-
yribonuclease I in RPMI 1640) at 37°C for 30 to 45 min [36].
Tissue residues were removed, and the resulting single cell
suspension was washed twice.
Synovial macrophages were isolated by positive magnetic
separation with CD14-conjugated magnetic beads (MACS;
Miltenyi Biotech) and a magnetic cell separator (MACS) in
accordance with the manufacturer's protocol.
Separation and stimulation of human T cells
Human T cells were isolated by counterflow elutriation from
PBMC as described above. T cells (106/ml) were cultured in
RPMI 1640 supplemented with 5% human AB serum, 2 mM
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin in
culture flasks (Techno Plastic Products AG, Trasadingen,
Switzerland) at 37°C and 5% CO2. To stimulate T cells, cul-
ture flasks were coated with 3.3 µg/ml monoclonal anti-CD3ε
antibodies (R & D Systems Inc., Minneapolis, MN, USA) and
soluble monoclonal anti-CD28 antibodies (BD Biosciences
Pharmingen, San Diego, CA, USA) were added to the medium
at a concentration of 0.8 µg/ml. After stimulation and incuba-
tion for 2 days, the cultures contained more than 90% CD3+
T cells as determined by flow cytometric analysis with a mon-
oclonal antibody against CD3. Cells were then washed three
times with PBS, fixed for 1 min with 0.05% glutaraldehyde
[11] and washed again three times with PBS. Fixed T cells
were stored for up to 2 weeks at 4°C.
This method of cell fixation was shown to inhibit blast transfor-
mation and TNF-α and IL-2 production in response to phorbol
12-myristate 13-acetate and ionomycin (data not shown).
Stimulation of human monocytes with T cells
Monocytes (1.5 × 106/ml) were cultured in RPMI 1640 sup-
plemented with 10% FCS, 2 mM glutamine, 100 U/ml penicil-
lin and 100 µg/ml streptomycin in 96-well culture plates
(Techno Plastic Products AG) at 37°C and 5% CO2. Fixed T
cells were added at a T cell : monocyte ratio of 7:1 (or any
other indicated ratio) and cells were incubated together for 24
hours (or any other indicated time). LPS (Escherichia coli
O55:B5, 100 ng/ml) was used as a positive control for mono-
cyte cytokine production. In some experiments, semi-permea-
ble Anopore membrane inserts (0.02 µm pore size; Nunc Life
Technologies) were fitted into the culture wells to separate the
monocytes (lower chamber) physically from the T cells (upper
chamber). After incubation, supernatants (200 µl per well, two
wells per condition) were harvested and stored at -140°C until
cytokine concentration was determined.
Data presented in this work show interactions of T cells with
monocytes from different donors. Similar results were
obtained when T cells were incubated with autologous mono-
cytes (data not shown).
Analysis of inhibitory effects of serum samples in co-
culture assays
In some cell–cell contact experiments, monocytes from
healthy donors were incubated with human sera either from
healthy individuals or from patients with RA. In these experi-
ments, FCS was replaced by 10% heat-inactivated, heterolo-
gous human serum matched for blood types. Sera were
incubated at 56°C for 30 min, at 70°C for 10 min or at 95°C
for 2 min before their addition to the co-culture assay. When
preincubation of monocytes (106/ml) with human sera was
performed, the monocytes were incubated in RPMI 1640 with
50% heat-inactivated (56°C for 30 minutes) serum at 20°C for
30 min. Monocytes were subsequently washed three times in
PBS before proceeding to the standard co-culture assay as
described above.
Cytokine measurement
TNF-α concentrations were determined with a commercially
available enzmye immunoassay (Beckman Coulter, Coulter-
Immunotech, Krefeld, Germany) in accordance with the manu-
facturer's protocol.
Apolipoprotein A-1 measurement
The serum concentration of apolipoprotein A-1 (ApoA-1) was
determined by nephelometry by using a commercially available
test kit (N antisera against human ApoA-1; Dade Behring, Lie-
derbach, Germany).
Statistical analysis
For statistical analysis, the software package Sigma Stat
(SPSS Inc., Chicago, IL, USA) was used. Before all compari-
sons, a normality test (Kolmogorov–Smirnov test with Lillie-
fors' correction) was performed. Student's t-test or the Mann–Arthritis Research & Therapy    Vol 7 No 6    Rossol et al.
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Whitney rank sum test were used for comparisons where
appropriate. To compare cytokine production in the patient
population with that of age-matched controls, pairwise com-
parisons were performed.
Results
T cell-dependent induction of TNF-α production in 
monocytes
To explore the requirements and dynamics of T cell-dependent
monocyte stimulation, an in vitro co-culture system using glu-
taraldehyde-fixed T cells as stimulator cells was established as
described previously [11]. As a positive control, LPS, a potent
stimulator of monocytes, was used in all experiments.
The addition of fixed, heterologous T cells preactivated by
immobilized anti-CD3 and anti-CD28 antibodies against
CD14+ peripheral-blood monocytes induced monocyte TNF
production in a manner dependent on T cell concentration
(Fig. 1a). Maximum stimulation of TNF-α production occurred
at T cell : monocyte ratios between 5:1 and 8:1. Contact of
monocytes with resting T cells even at the highest T cell :
monocyte ratio did not lead to significant TNF-α production in
those experiments (data not shown), and induced only a mod-
est but not statistically significant increase in a later set of co-
culture experiments (Fig. 1b). All subsequent experiments
were performed at a T cell : monocyte ratio of 7:1, which was
also used in several previously published studies with this
experimental system [23,25,37]. To analyse the influence of
Figure 1
T cell induced production of TNF-α by monocytes from healthy donors T cell induced production of TNF-α by monocytes from healthy donors. (a) Fixed stimulated T cells induce tumour necrosis factor (TNF)-α produc-
tion by monocytes in a dose-dependent manner. Peripheral-blood T cells (106/ml) were cultured for 48 hours in the presence of immobilized anti-
CD3 (3.3 µg/ml) and soluble anti-CD28 (0.8 µg/ml) antibodies. Stimulated T cells were fixed and incubated for 24 hours with freshly isolated mono-
cytes (1.5 × 106/ml) at the indicated ratios. Values are means ± SEM from four different experiments. (b) Cell–cell contact is necessary for T cell-
induced production of TNF-α in monocytes. Peripheral-blood T cells (106/ml) were cultured for 48 hours in the presence or absence of immobilized 
anti-CD3 (3.3 µg/ml) and soluble anti-CD28 (0.8 µg/ml) antibodies. Stimulated (sTc) and resting (rTc) T cells were fixed and incubated for 24 hours 
with freshly isolated monocytes (1.5 × 106/ml) at a ratio of 7:1 in a transwell system as described in the Materials and methods section. T cells and 
monocytes were physically separated by the semi-permeable membrane (with insert) or had direct cell–cell contact (without insert). Lipopolysaccha-
ride (LPS; 100 ng/ml) was used as a positive control. Values are means ± SEM for experiments with three different donors. (c) T cell-induced TNF-
α production by monocytes is time-dependent. Peripheral-blood T cells (106/ml) were cultured for 48 hours in the presence or absence of immobi-
lized anti-CD3 (3.3 µg/ml) and soluble anti-CD28 (0.8 µg/ml) antibodies. Stimulated (sTc) and resting (rTc) T cells were fixed and incubated for the 
indicated durations with freshly isolated monocytes (1.5 × 106/ml) at a ratio of 7:1. Values are means ± SEM for experiments with three different 
donors. Levels of significance: * P < 0.05, *** P < 0.001.Available online http://arthritis-research.com/content/7/6/R1189
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the T cell origin on the monocyte response mediated by T cell
contact, autologous and heterologous co-cultures were per-
formed. Contact of monocytes with autologous or heterolo-
gous preactivated T cells led to the same amount of TNF-α
(data not shown), so a heterologous co-culture system was
used for subsequent experiments.
To exclude the influence of soluble mediators released by the
fixed T cells, transwell experiments using a tissue culture plate
insert with a microporous membrane with a pore size of 0.02
µm were performed. Monocytes placed in the bottom chamber
of the transwell system, which had no physical contact with
the prestimulated T cells present in the top chamber, failed to
produce detectable amounts of TNF-α, indicating that cell-
contact-dependent stimuli were necessary for monocyte acti-
vation (Fig. 1b). When the time course of monocyte TNF-α
production after cell contact with preactivated T cells was ana-
lysed, a distinct kinetic profile comparable to that seen after
stimulation with LPS was observed (Fig. 1c).
T cell-induced TNF-α production of peripheral 
monocytes from patients with RA is decreased compared 
with TNF-α production in healthy donors
Although T cell–monocyte interaction has been proposed to
contribute to the abundant TNF-α production seen in this dis-
ease, the role of peripheral monocytes from patients with RA
in this interaction has not yet been investigated. To address
this issue, CD14+ cells were isolated from the peripheral cir-
culation of patients with RA and from age-matched controls by
negative immunomagnetic separation and were subsequently
used in the co-culture assay.
As seen in Fig. 2a, co-incubation of monocytes of patients with
RA with preactivated fixed T cells resulted in significantly lower
levels of TNF-α than in the controls. To exclude a global defect
of monocyte cytokine production in RA, monocytes from
patients with RA were stimulated with LPS as a positive con-
trol. In contrast to the T cell-induced TNF-α response, no dif-
ference in LPS-induced TNF-α production by monocytes was
found between patients with RA and healthy controls.
In view of this unexpected finding, and with regard to the piv-
otal role of TNF-α in synovitic joints in RA, CD14+ cells were
separated with CD14+ MicroBeads from synovial membrane
biopsies from patients with RA, and tested for their capacity to
produce TNF-α in the co-culture system. In contrast to the
peripheral-blood monocytes from patients with RA, synovial
mononuclear cells were found to be highly preactivated and to
produce large amounts of TNF-α in the presence of resting T
cells. In addition, they were found to increase their TNF-α pro-
duction further after co-culture with preactivated fixed T cells
and after stimulation with LPS (Fig. 2b). In parallel experi-
ments, the influence of cell separation by CD14+ MicroBeads
and by negative immunomagnetic purification was compared.
No significant differences between the two separation tech-
niques with regard to the TNF-α response of synovial mono-
cytes/macrophages were detectable. Most notably, however,
the concentrations of TNF-α elicited in synovial monocytes/
macrophages by T cell contact were fivefold to tenfold higher
than those of peripheral-blood monocytes from either healthy
donors or patients with RA under comparable experimental
conditions. This result indicates that synovial cell populations
are indeed likely to be the major source of the increased TNF-
α load in RA, whereas peripheral monocytes are not.
To assess the influence of immunosuppressive therapy on T
cell-dependent monocyte TNF-α production, patients were
stratified into two groups: one of patients who were receiving
DMARD therapy at the time of the study (n = 14) and one of
patients with recent-onset RA who had not received steroid or
DMARD medication before study enrolment (n = 6). T cell-
dependent TNF-α production by peripheral-blood monocytes
in the six patients with recent-onset RA was not significantly
different (635 ± 210 pg/ml, n = 6) from that of patients who
had received therapy (835 ± 233 pg/ml, n = 14).
When TNF-α production by monocytes from untreated
patients with RA, who were age-matched with healthy con-
trols, was analysed, monocytes from untreated patients pro-
duced significantly less TNF-α in a T cell-dependent manner
(635 ± 210 pg/ml, n = 6) than those from controls (1,648 ±
398 pg/ml, n = 6, P = 0.048). Fig. 2c depicts the results from
patients treated with methotrexate (n = 5), untreated patients
with RA (n = 6) and age-matched healthy controls (n = 6).
Analysis of clinical and laboratory parameters of all patients
tested did not reveal any association between T cell-depend-
ent cytokine production and disease activity, RF status, immu-
nogenetic markers, disease duration or the patient's age.
Similarly, no age-dependent decline of cytokine production
was observed in the age-matched control group.
RA sera inhibit T cell-dependent TNF-α production by 
monocytes from healthy donors
Since monocytes from patients with RA were able to respond
to LPS stimulation similarly to monocytes from healthy con-
trols, we proposed that their diminished response in the co-
culture assay was due to a disease-specific inhibitory mecha-
nism present in the systemic circulation of patients with RA.
To test this hypothesis, serum exchange experiments were
performed, in which monocytes from healthy donors were
incubated with prestimulated T cells in the presence of 10%
serum from either patients with RA or healthy controls. To
avoid monocyte stimulation through blood type antigen-spe-
cific antibodies in the RA sera, patients and controls were
matched for blood groups.
The addition of sera from healthy controls to the co-cultures
was found to inhibit T cell induced production of TNF-α whenArthritis Research & Therapy    Vol 7 No 6    Rossol et al.
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compared with control cultures containing culture medium
supplemented with FCS (Fig. 3a). This is in line with previous
observations reporting the inhibition of T cell-dependent
monocyte activation by serum from healthy controls [25].
When sera from patients with RA were added, they also sup-
pressed TNF-α production (Fig. 3a). In comparison with the
control sera, this inhibition was found to be significantly
stronger. A difference between RA sera and control sera was
also seen in experiments in which monocytes were preincu-
bated with either sera and then co-cultured with T cells in the
standard FCS-supplemented culture medium (Fig. 3b).
Whereas preincubation of monocytes in RA sera was found to
induce the inhibitory effect, preincubation with healthy sera
was not sufficient to influence TNF-α production (Fig. 3b). In
these experiments, we used sera from patients with active RA
that had previously been shown to exhibit a pronounced inhib-
itory activity.
To analyse the influence of clinical parameters of disease
activity on the inhibitory activity exhibited by the sera from
patients with RA, sera from 20 patients with non-active dis-
ease were compared with sera from patients with high disease
activity (for definition of active and non-active RA see the
Patients and methods section). The results in Fig. 4a indicate
that the inhibitory effect of RA sera is evident only in patients
with active disease. To explore the disease specificity of this
inhibitory activity further, sera from patients with ankylosing
Figure 2
Decreased T cell induced production of TNF-α in monocytes from RA patients Decreased T cell induced production of TNF-α in monocytes from RA patients. (a) T cell-induced tumour necrosis factor (TNF)-α secretion by mono-
cytes from patients with rheumatoid arthritis (RA) is decreased in comparison with those from healthy controls. Peripheral-blood T cells (106/ml) 
were cultured for 48 hours in the presence or absence of immobilized anti-CD3 (3.3 µg/ml) and soluble anti-CD28 (0.8 µg/ml) antibodies. Stimu-
lated (sTc) and resting (rTc) T cells were fixed and incubated with freshly isolated monocytes (1.5 × 106/ml) at a ratio of 7:1. After 24 hours, the con-
centration of TNF-α was measured in the supernatant. Lipopolysaccharide (LPS; 100 ng/dl) was used as a positive control. Data are means ± SEM 
of values from 20 patients with RA and 20 age-matched controls. (b) Macrophages separated from the synovial membrane of patients with RA pro-
duce large amounts of TNF-α after contact with preactivated T cells. Stimulated (sTc) and resting (rTc) T cells were fixed and incubated with freshly 
isolated synovial macrophages from patients with RA (1.5 × 106/ml) at a ratio of 7:1. After 24 hours, the concentration of TNF-α was measured in 
the supernatant. LPS (100 ng/ml) was used as a positive control. Data are means ± SEM of values from six independent experiments. Level of sig-
nificance: not significant. (c) Decrease in T cell-induced TNF-α secretion by monocytes from patients with RA is independent of previous and current 
treatments. The graph depicts the T cell-induced TNF-α production by monocytes of patients with RA either receiving methotrexate (MTX; n = 5) or 
not receiving immunosuppressive treatment (untreated; n = 6). For comparison, results for six age-matched controls are given (P < 0.05, significant 
difference compared with untreated patients).Available online http://arthritis-research.com/content/7/6/R1189
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spondylitis and with psoriatic arthritis were used as two con-
trol groups with chronic, inflammatory autoimmune diseases.
Figure 4b shows that sera from the disease controls did not
inhibit monocyte cytokine production mediated by T cell con-
tact and did not differ from those from healthy individuals.
The selected RA sera with pronounced inhibitory activity,
which were used in the preincubation experiments, were also
used for experiments determining the heat resistance of the
inhibitory activity. The sera were incubated at different temper-
atures and added to the standard co-culture assay. As seen in
Fig. 5, heating the sera to 56°C (which was routinely used in
the previous experiments) preserved the inhibitory activity,
whereas increasing the temperature to 70 or 95°C resulted in
a loss of that inhibitory activity. Thus, the inhibitory activity is
due to heat-labile factors.
Direct inhibition of T cell-dependent monocyte activation has
been described previously for the serum protein ApoA-1. To
analyse the contribution of ApoA-1 to the inhibitory activity
found in sera from patients with RA, ApoA-1 concentrations
were determined in sera from patients with active and non-
active RA and from controls. The results depicted in Fig. 6a
show that ApoA-1 concentrations in sera from patients with
active RA are not different from those of the controls, but are
significantly decreased in patients with non-active disease.
However, when the inhibitory activity of each serum from
patients with active disease was plotted against ApoA-1 con-
centrations, a significant correlation became apparent,
because the inhibitory effect increased with increasing ApoA-
1 concentration (correlation coefficient R  = -0.527, P  =
0.016; Fig. 6b). No correlation between ApoA-1 concentration
and inhibitory activity was found in the sera from controls and
from patients with non-active disease (data not shown).
Discussion
Direct cell–cell contact of monocytes/macrophages with pre-
activated T lymphocytes leads to the secretion of high levels of
proinflammatory cytokines and has been implied in the
disturbed cytokine balance seen in RA [21,29,38]. As shown
Figure 3
Sera from RA patients inhibit T cell-induced TNF-α production by monocytes from healthy donors Sera from RA patients inhibit T cell-induced TNF-α production by monocytes from healthy donors. (a) Peripheral-blood T cells (106/ml) were cul-
tured for 48 hours in the presence of immobilized anti-CD3 (3.3 µg/ml) and soluble anti-CD28 (0.8 µg/ml) antibodies. The cells were fixed and incu-
bated for 24 hours with freshly isolated monocytes (1.5 × 106/ml) at a ratio of 7:1. The co-incubation assay was performed in the presence of 10% 
FCS, 10% serum from patients (serum [RA]) or from healthy donors (serum [control]). All data are expressed as percentages of TNF-α produced in 
the 10% FCS containing co-culture system (100%). Data are means ± SEM for 10 independent experiments; levels of significance are as indicated. 
(b) Monocytes from healthy donors were preincubated with 50% control sera (nine donors) or RA sera (six sera from patients with RA, which were 
previously found to inhibit T cell-dependent monocyte activation) and then washed thoroughly three times. Co-culture experiments were performed 
as described in the text in medium supplemented with 10% FCS. All data are expressed as percentages of TNF-α produced in the co-culture system 
containing 10% FCS. Data are means ± SEM for four independent experiments; levels of significance are as indicated.Arthritis Research & Therapy    Vol 7 No 6    Rossol et al.
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here and described previously, the most likely candidates
responsible for the T cell-dependent TNF-α production are
synovial macrophages from patients with RA. However, in
some studies an involvement of peripheral-blood monocytes in
the process of this chronic disease has also been suggested
[30-32]. This raises the question of the contribution of mono-
cytes to the increased TNF-α load seen in patients with RA. To
address this we used monocytes from patients with RA in the
co-culture system, because previous studies have examined
monocytes from healthy donors only. The finding that mono-
cytes from patients with RA produced less TNF-α than mono-
cytes from controls was unexpected in view of the proposed
contribution of this interaction to the excessive TNF-α levels
observed in this disease. Monocytes from patients with RA
and controls did not produce any cytokines in the absence of
additional stimuli, indicating that peripheral-blood monocytes
were not preactivated and that the cell separation techniques
used did not lead to artificial ex vivo stimulation of the
monocytes.
The induction of TNF-α unequivocally required direct cell con-
tact of the monocytes with T cells, which excludes the possi-
bility that the stimuli of cytokine production are soluble
mediators released from the fixed T lymphocytes. Comparing
the TNF-α levels produced by synovial monocytes/macro-
Figure 4
Inhibition of T cell-induced TNF-α production by monocytes is specific for active RA Inhibition of T cell-induced TNF-α production by monocytes is specific for active RA. (a) Preactivated peripheral-blood T cells (106/ml; see Materials 
and methods) were fixed and incubated for 24 hours with freshly isolated peripheral-blood monocytes (1.5 × 106/ml) at a ratio of 7:1. The co-incu-
bation assay was performed in the presence of 10% FCS, 10% serum from healthy donors (serum [control], n = 10), from patients with active RA 
(serum [aRA], n = 20) or from patients with non-active RA (serum [nRA], n = 20). All data are expressed as percentages of TNF-α produced in the 
co-culture system containing 10% FCS. Data are means ± SEM; levels of significance are as indicated. (b) Co-incubation assays (see (a)) were per-
formed in the presence of 10% FCS, 10% serum from healthy donors (serum [control], n = 10)), serum from patients with psoriatic arthritis (serum 
[PsA], n = 9) or from patients with ankylosing spondylitis (serum [aSp], n = 9). All data are expressed as percentages of TNF-α produced in the co-
culture system containing 10% FCS. Data are means ± SEM; levels of significance are as indicated.
Figure 5
Inhibitory activity of rheumatoid arthritis (RA) sera is not heat stable Inhibitory activity of rheumatoid arthritis (RA) sera is not heat stable. Six 
sera from patients with RA, which previously were found to strongly 
inhibit T cell-dependent monocyte activation were incubated at 56°C 
for 30 min, at 70°C for 10 min or at 95°C for 2 min. Co-culture experi-
ments were performed in the presence of 10% FCS or 10% RA sera. 
All data are expressed as percentages of tumour necrosis factor-α pro-
duced in the co-culture system containing 10% FCS. Data are means ± 
SEM from six independent experiments. P = 0.002 (significant differ-
ence from the 100% values).Available online http://arthritis-research.com/content/7/6/R1189
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phages with those produced by peripheral monocytes clearly
shows that monocytes are not major contributors to the TNF-
α load in RA.
The experiments presented here also indicate that the
reduced production of TNF-α is not an intrinsic feature of
monocytes from patients with RA, because the monocytes are
capable of a full TNF-α response to stimulation with LPS. This
is in agreement with previous reports about the LPS response
of monocytes from patients with RA [39,40], although the evi-
dence is somewhat controversial [41,42]. Furthermore, when
measuring other cytokines such as IL-1β, IL-8 and IL-10, we
observed that monocytes from patients with RA responded
equally well to LPS as did monocytes from controls (data not
shown).
Because monocytes from patients with RA are fully capable of
producing cytokines, the most likely explanation for the sup-
pression of the T cell-dependent TNF-α response is the pres-
ence of regulatory serum factors. The serum protein ApoA-1
has been shown to act as a regulator of cytokine production
[25]. The authors found that autologous serum from healthy
controls was able to inhibit T cell-dependent TNF-α produc-
tion in monocytes. They identified ApoA-1 as the molecule
blocking the contact-mediated activation of monocytes. ApoA-
1 is regarded as a 'negative' acute-phase protein and has
been described as being present only in reduced levels in sera
from patients with RA [43-45] and juvenile idiopathic arthritis
[46], which makes it an unlikely candidate for systemic
counter-regulation of cytokine production in RA. High levels of
ApoA-1 have been found in the local synovitic environment in
RA, where the molecule seems to act as an inhibitory regulator
of cytokine production [47]. In its absence, one would expect
cytokines to reach extremely high levels.
The present results confirm that patients with RA do not have
an increased serum concentration of ApoA-1 compared with
that of healthy controls. Consequently, the strong inhibitory
activity of RA sera cannot be explained by an increased ApoA-
1 concentration alone, although the result of a significant cor-
relation between ApoA-1 concentration and inhibitory serum
activity is remarkable.
The results are best explained by additional inhibitory factors
that seem to be present in RA sera and seem to bind to the
monocyte cell surface, as indicated by two indirect lines of evi-
dence. First, monocytes from patients with RA cultured in FCS
produced less TNF-α in response to activated T cells than
those from controls (Fig. 4), which indicates that the soluble
factor is transferred from the in vivo situation to the co-culture
assay. The most likely mode of transfer of the factors would be
in cell-bound form on the surface of the monocytes. Second,
preincubation of monocytes from healthy controls in RA sera
was sufficient to inhibit TNF-α production, and extensive
washing did not abolish the inhibitory effect. Again, 'coating' of
the monocyte surfaces by the suggested inhibitory factors,
which prevents the full interaction between monocytes and T
cells, might account for the reduced TNF-α production.
The inhibitory factor(s) described here seem to be specific for
RA, and are most pronounced in patients with active disease.
It can be proposed that, with increasing disease activity of RA,
Figure 6
ApoA-1 concentrations are decreased in non-active RA but correlate with the inhibitory serum activity in active RA ApoA-1 concentrations are decreased in non-active RA but correlate with the inhibitory serum activity in active RA. (a) Box plot depicting ApoA-1 
concentrations in sera from healthy controls (n = 20), in patients with active RA (n = 20) and in patients with non-active disease (n = 20). Levels of 
significance are given; n.s., not significant. (b) Scatter plot depicting the correlation between ApoA-1 concentrations and inhibitory serum activity in 
sera from patients with active RA. Each data point represents the ApoA-1 concentration in relation to the inhibitory activity. Tumour necrosis factor 
(TNF)-α production in the co-culture system containing 10% FCS is set to 100%. The regression line illustrates the negative correlation between the 
two parameters (correlation coefficient R = -0.527; P = 0.016).Arthritis Research & Therapy    Vol 7 No 6    Rossol et al.
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ApoA-1 (in addition to other factors) becomes upregulated
and thus contributes to the downregulation of contact-medi-
ated TNF-α production by monocytes.
Conclusion
The data presented provide evidence for the existence of
inhibitory, heat-labile factors in the serum of patients with RA,
which downregulate the activation of peripheral-blood mono-
cytes brought about by T cell contact. The possible physiolog-
ical role of this regulatory mechanism and the specific
molecules mediating the suppression remain to be
determined.
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